We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Troubled by Liver Toxicity from Cempra’s Antibiotic Ahead of Advisory Meeting
FDA Troubled by Liver Toxicity from Cempra’s Antibiotic Ahead of Advisory Meeting
FDA reviewers expressed strong concerns over the possibility of liver damage related to solithromycin treatment ahead of an advisory committee meeting Friday on whether the drug should be approved as an antibiotic for community-acquired bacterial pneumonia.